{"id":146464,"date":"2026-04-19T16:24:27","date_gmt":"2026-04-19T20:24:27","guid":{"rendered":"https:\/\/medcitynews.com\/?p=146464"},"modified":"2026-04-19T19:14:39","modified_gmt":"2026-04-19T23:14:39","slug":"is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in","status":"publish","type":"post","link":"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/","title":{"rendered":"Is Shah Capital\u2019s Criticism of Novavax Fair? A Wall Street Analyst Weighs In"},"content":{"rendered":"\n<p>In May 2024, Shah Capital, a hedge fund in North Carolina, <a href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/05\/20\/2884727\/0\/en\/Shah-Capital-Withdraws-Proxy-Campaign-Against-Re-Election-of-Directors-at-Novavax-s-2024-Annual-Meeting.html\" id=\"https:\/\/www.globenewswire.com\/news-release\/2024\/05\/20\/2884727\/0\/en\/Shah-Capital-Withdraws-Proxy-Campaign-Against-Re-Election-of-Directors-at-Novavax-s-2024-Annual-Meeting.html\" target=\"_blank\" rel=\"noreferrer noopener\">withdrew from its proxy fight<\/a> against Novavax&#8217;s board of directors when the vaccine maker <a href=\"https:\/\/www.prnewswire.com\/news-releases\/novavax-and-sanofi-announce-co-exclusive-licensing-agreement-to-co-commercialize-covid-19-vaccine-and-develop-novel-covid-19-influenza-combination-vaccines-302142096.html\" id=\"https:\/\/www.prnewswire.com\/news-releases\/novavax-and-sanofi-announce-co-exclusive-licensing-agreement-to-co-commercialize-covid-19-vaccine-and-develop-novel-covid-19-influenza-combination-vaccines-302142096.html\" target=\"_blank\" rel=\"noreferrer noopener\">announced a billion-dollar deal with Sanofi<\/a>. At the time, Shah Capital signaled that backing down &#8220;does not mean our engagement is at an end.\u201d<\/p>\n\n\n\n<p>Sure enough, less than two years later, the activist investment firm continues to be a headache. Earlier this month, Himanshu Shah, founder of the eponymous Shah Capital, <a href=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2026\/04\/Shah-Capital-NVAX-BOD-Letter-13D-Apr-2026.docx.pdf\" id=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2026\/04\/Shah-Capital-NVAX-BOD-Letter-13D-Apr-2026.docx.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">fired off a letter<\/a> signaling deep dissatisfaction with the Gaithersburg, Maryland company&#8217;s financial performance.<\/p>\n\n\n\n<p>&#8220;As a large and long-term 9% shareholder, we are writing to formally notify you of our intent to vote AGAINST the re-election of board nominees and AGAINST the executive compensation package at the upcoming 2026 Annual Meeting. Your tenure has overseen a DESTRUCTION of shareholder value \u2014 a direct result of chronic operational shortcomings and failures on fiduciary duty,&#8221; Shah&#8217;s letter, dated April 8, read.<\/p>\n\n\n\n<p>The letter highlighted several failures including the following:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Novavax&#8217;s 2024 Sanofi partnership is not yet fruitful \u2014 in fact, Shah said that last year&#8217;s meager $22 million sales of Nuvaxovid, the non-mRNA Covid vaccine, which Sanofi took over after the 2024 agreement, is &#8220;unfathomable&#8221; and &#8220;unacceptable.&#8221;<\/li>\n\n\n\n<li>The company has not controlled costs and issued a pessimistic 2026 revenue outlook.<\/li>\n\n\n\n<li>Novavax suffers from low institutional credibility leading many investors to hold short positions on its stock, despite the company&#8217;s partnerships with <a href=\"https:\/\/ir.novavax.com\/press-releases\/2026-01-20-Novavax-Announces-Entering-into-a-License-Agreement-with-Pfizer\" id=\"https:\/\/ir.novavax.com\/press-releases\/2026-01-20-Novavax-Announces-Entering-into-a-License-Agreement-with-Pfizer\" target=\"_blank\" rel=\"noreferrer noopener\">Pfizer<\/a> and Sanofi.<\/li>\n<\/ul>\n\n\n\n<p>But is the criticism fair? <\/p>\n\n\n\n<p>After all, Novavax \u2014 whose stock price has plummeted to under $10 from a high of about $290 in 2021 \u2014 is not the only Covid vaccine maker that has wrestled with lower demand for its product. Moderna, which became a household name during the pandemic for its mRNA vaccine, saw its stock price swoon from a whopping $450 in 2021 to the mid-$20 range in late 2025, though the share price has since doubled to more than $50. BioNTech, which collaborated with Pfizer on their Covid mRNA vaccine, saw its stock price drop from $389 in 2021 to nearly $80 in 2025, before regaining some steam \u2014 it trades over $100 today. Despite the latter two company&#8217;s stock price is far off from their pandemic-prompted highs, no activist investor is attacking Moderna or BioNTech \u2014 at least not publicly.<\/p>\n\n\n\n<p>One Wall Street analyst who has a &#8220;buy&#8221; rating on Novavax&#8217;s stock acknowledged that Shah&#8217;s criticisms are not unfounded though he didn&#8217;t fully agree with all the criticisms.<\/p>\n\n\n\n<p>&#8220;You&#8217;ve seen Moderna&#8217;s stock price, you&#8217;ve seen BioNTech,&#8221; said Mayank Mamtani, senior vice president and group head of healthcare at B. Riley Securities in an interview last week. &#8220;But again, Moderna and BioNTech have pivoted. Now they&#8217;re pipelines to oncology. And we have a very actionable catalyst for both those companies. And that is not the case \u2014 I think that is where the disconnect is with Novavax.&#8221;<\/p>\n\n\n\n<p>He added that Novavax has good partnerships with Pfizer and Sanofi but there isn&#8217;t great visibility with how things are progressing there. Sanofi has licensed Novavax&#8217;s Matrix-M technology and is developing the Covid-19-Influenza-Combination (CIC) vaccine. Mamtani said that Sanofi has publicly said that the the CIC vaccine will be one of the company&#8217;s top three products that could in the future help to offset sales of  its blockbuster drug Dupixent when the expected loss of exclusivity occurs. Novavax stands to get royalties from the sale of this vaccine once clinical trials are done and the product is commercialized with FDA&#8217;s blessing.<\/p>\n\n\n\n<p>&#8220;But [Sanofi has] not made any such announcements that we&#8217;re going to Phase 3 and we are going to provide data next year, [or] we&#8217;re going to file,&#8221; he said. &#8220;So that&#8217;s what we are waiting for. That&#8217;s the big catalyst.&#8221;<\/p>\n\n\n\n<p>In fact, in his April 9 research note, Mamtani stressed that once Sanofi provides input on Phase 3 study design and execution, Novavax will be able to earn a $125 million milestone payment as per their agreement. But when Sanofi obliges the market with this information is that company&#8217;s prerogative \u2014 which, as Mamtani noted, is &#8220;largely independent of Novavax&#8217;s governance situation.&#8221;<\/p>\n\n\n\n<p>This notwithstanding, does he agree with Shah&#8217;s call for changes to the board? In his letter, Shah recommended Novavax&#8217;s <a href=\"https:\/\/www.novavax.com\/leadership\" id=\"https:\/\/www.novavax.com\/leadership\" target=\"_blank\" rel=\"noreferrer noopener\">board size<\/a> be reduced to five members from eight. He also urged the election of &#8220;new members with emphasis on pragmatic entrepreneurial experience&#8221; to turn around the financial fortunes of Novavax.<\/p>\n\n\n\n<p>&#8220;I think the governance can improve,&#8221; Mamtani said.<\/p>\n\n\n\n<p>He wouldn&#8217;t comment on individual directors but implied fresh blood was needed. In his letter, Shah went so far as to say that Novavax&#8217;s current equity valuation &#8220;shows that its leadership is pursuing tenures and not shareholder value.&#8221; Now, to be fair to Novavax, the company did add two members to its board in 2025, though one director, Richard Douglas, has held a board seat for more than a quarter of a century.<\/p>\n\n\n\n<p>While tacitly agreeing with Shah on the make-up of the board, Mamtani, who has a price target of $18 for Novavax&#8217;s stock, disagrees with Shah on cost-cutting.<\/p>\n\n\n\n<p>&#8220;I&#8217;ll be fair, Himanshu is pushing them to cut costs, but they&#8217;ll lose good talent &#8230; especially when they&#8217;re trying to portray a good image to Pharma that they&#8217;re a stable company,&#8221; Mamtani declared, noting the relationships with partners like Sanofi and Pfizer. &#8220;The core DNA of the company is damaged, and it becomes a dysfunctional organization.&#8221;<\/p>\n\n\n\n<p>But ultimately, he does believe Novavax&#8217;s stock price will go up, even if slower than what Shah would like to see. For the time being, Mamtani is reassured by the recent <a href=\"https:\/\/ir.novavax.com\/press-releases\/2026-03-30-Novavax-Appoints-Dr-Robert-Walker-as-Executive-Vice-President-and-Head-of-Research-Development\" id=\"https:\/\/ir.novavax.com\/press-releases\/2026-03-30-Novavax-Appoints-Dr-Robert-Walker-as-Executive-Vice-President-and-Head-of-Research-Development\" target=\"_blank\" rel=\"noreferrer noopener\">R&amp;D leadership consolidation under Dr. Robert Walker<\/a> that will reduce costs. <\/p>\n\n\n\n<p><em>Photo: champc, Getty Images<\/em><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Himanshu Shah, an activist investor and large shareholder of Novavax, whose stock has plummeted over the years, believes the company should cut costs more aggressively, reduce the size of its board, and do more to prop up its financial performance. But are the criticisms valid?<\/p>\n","protected":false},"author":25944,"featured_media":15816,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"featured_image_focal_point":[],"homepage_placement":"top","homepage_placements":{"top":true,"featured":true,"sidebar":false},"homepage_alternative_layout":false,"featured_categories":[69],"hide_from_feed":false,"footnotes":""},"categories":[69,63],"tags":[42355,10854,246,6573],"class_list":["post-146464","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-daily","tag-biopharma-nl","tag-novavax","tag-pfizer","tag-sanofi"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Is Shah Capital&#039;s Criticism of Novavax Fair? A Wall Street Analyst Weighs In - MedCity News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Is Shah Capital&#039;s Criticism of Novavax Fair? A Wall Street Analyst Weighs In - MedCity News\" \/>\n<meta property=\"og:description\" content=\"Himanshu Shah, an activist investor and large shareholder of Novavax, whose stock has plummeted over the years, believes the company should cut costs more aggressively, reduce the size of its board, and do more to prop up its financial performance. But are the criticisms valid?\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/\" \/>\n<meta property=\"og:site_name\" content=\"MedCity News\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-19T20:24:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-19T23:14:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/05\/arrow-decrease-champc-getty-images.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"747\" \/>\n\t<meta property=\"og:image:height\" content=\"467\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Arundhati Parmar\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@aparmarbb\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Arundhati Parmar\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/\"},\"author\":{\"name\":\"Arundhati Parmar\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/fa4cfd6f9f2b60692f97a9e42d901557\"},\"headline\":\"Is Shah Capital\u2019s Criticism of Novavax Fair? A Wall Street Analyst Weighs In\",\"datePublished\":\"2026-04-19T20:24:27+00:00\",\"dateModified\":\"2026-04-19T23:14:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/\"},\"wordCount\":960,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/05\/arrow-decrease-champc-getty-images.jpg\",\"keywords\":[\"biopharma nl\",\"Novavax\",\"Pfizer\",\"Sanofi\"],\"articleSection\":[\"BioPharma\",\"Daily\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/\",\"url\":\"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/\",\"name\":\"Is Shah Capital's Criticism of Novavax Fair? A Wall Street Analyst Weighs In - MedCity News\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/05\/arrow-decrease-champc-getty-images.jpg\",\"datePublished\":\"2026-04-19T20:24:27+00:00\",\"dateModified\":\"2026-04-19T23:14:39+00:00\",\"author\":{\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/fa4cfd6f9f2b60692f97a9e42d901557\"},\"breadcrumb\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#primaryimage\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/05\/arrow-decrease-champc-getty-images.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/05\/arrow-decrease-champc-getty-images.jpg\",\"width\":747,\"height\":467},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medcitynews.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Is Shah Capital&#8217;s Criticism of Novavax Fair? A Wall Street Analyst Weighs In\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medcitynews.com\/#website\",\"url\":\"https:\/\/medcitynews.com\/\",\"name\":\"MedCity News\",\"description\":\"Healthcare technology news, life science current events\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medcitynews.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/fa4cfd6f9f2b60692f97a9e42d901557\",\"name\":\"Arundhati Parmar\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2016\/11\/Arundhati-Parmar_avatar_1478093247-96x96.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2016\/11\/Arundhati-Parmar_avatar_1478093247-96x96.jpg\",\"caption\":\"Arundhati Parmar\"},\"description\":\"Arundhati Parmar is VP and Editor-in-Chief at MedCity News. In this role, she oversees MedCity's news coverage as well as develops the content for several conferences that the publication hosts. Previously, she was Senior Editor at UBM's Medical Device + Diagnostic Industry. Arundhati has three degrees from three continents - a Bachelor of Arts in English from Jadavpur University, Kolkata, India; a Masters in English Literature from the University of Sydney, Australia and a Masters in Journalism from Northwestern University in Chicago. She has sworn never to enter a classroom again. Contact her at aparmar@medcitynews.com&gt;.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/arundhati-parmar\/\",\"https:\/\/x.com\/aparmarbb\"],\"url\":\"https:\/\/medcitynews.com\/author\/aparmar\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Is Shah Capital's Criticism of Novavax Fair? A Wall Street Analyst Weighs In - MedCity News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/","og_locale":"en_US","og_type":"article","og_title":"Is Shah Capital's Criticism of Novavax Fair? A Wall Street Analyst Weighs In - MedCity News","og_description":"Himanshu Shah, an activist investor and large shareholder of Novavax, whose stock has plummeted over the years, believes the company should cut costs more aggressively, reduce the size of its board, and do more to prop up its financial performance. But are the criticisms valid?","og_url":"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/","og_site_name":"MedCity News","article_published_time":"2026-04-19T20:24:27+00:00","article_modified_time":"2026-04-19T23:14:39+00:00","og_image":[{"width":747,"height":467,"url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/05\/arrow-decrease-champc-getty-images.jpg","type":"image\/jpeg"}],"author":"Arundhati Parmar","twitter_card":"summary_large_image","twitter_creator":"@aparmarbb","twitter_misc":{"Written by":"Arundhati Parmar","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#article","isPartOf":{"@id":"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/"},"author":{"name":"Arundhati Parmar","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/fa4cfd6f9f2b60692f97a9e42d901557"},"headline":"Is Shah Capital\u2019s Criticism of Novavax Fair? A Wall Street Analyst Weighs In","datePublished":"2026-04-19T20:24:27+00:00","dateModified":"2026-04-19T23:14:39+00:00","mainEntityOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/"},"wordCount":960,"commentCount":0,"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/05\/arrow-decrease-champc-getty-images.jpg","keywords":["biopharma nl","Novavax","Pfizer","Sanofi"],"articleSection":["BioPharma","Daily"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/","url":"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/","name":"Is Shah Capital's Criticism of Novavax Fair? A Wall Street Analyst Weighs In - MedCity News","isPartOf":{"@id":"https:\/\/medcitynews.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#primaryimage"},"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/05\/arrow-decrease-champc-getty-images.jpg","datePublished":"2026-04-19T20:24:27+00:00","dateModified":"2026-04-19T23:14:39+00:00","author":{"@id":"https:\/\/medcitynews.com\/#\/schema\/person\/fa4cfd6f9f2b60692f97a9e42d901557"},"breadcrumb":{"@id":"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#primaryimage","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/05\/arrow-decrease-champc-getty-images.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/05\/arrow-decrease-champc-getty-images.jpg","width":747,"height":467},{"@type":"BreadcrumbList","@id":"https:\/\/medcitynews.com\/2026\/04\/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medcitynews.com\/"},{"@type":"ListItem","position":2,"name":"Is Shah Capital&#8217;s Criticism of Novavax Fair? A Wall Street Analyst Weighs In"}]},{"@type":"WebSite","@id":"https:\/\/medcitynews.com\/#website","url":"https:\/\/medcitynews.com\/","name":"MedCity News","description":"Healthcare technology news, life science current events","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medcitynews.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/fa4cfd6f9f2b60692f97a9e42d901557","name":"Arundhati Parmar","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/image\/","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2016\/11\/Arundhati-Parmar_avatar_1478093247-96x96.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2016\/11\/Arundhati-Parmar_avatar_1478093247-96x96.jpg","caption":"Arundhati Parmar"},"description":"Arundhati Parmar is VP and Editor-in-Chief at MedCity News. In this role, she oversees MedCity's news coverage as well as develops the content for several conferences that the publication hosts. Previously, she was Senior Editor at UBM's Medical Device + Diagnostic Industry. Arundhati has three degrees from three continents - a Bachelor of Arts in English from Jadavpur University, Kolkata, India; a Masters in English Literature from the University of Sydney, Australia and a Masters in Journalism from Northwestern University in Chicago. She has sworn never to enter a classroom again. Contact her at aparmar@medcitynews.com&gt;.","sameAs":["https:\/\/www.linkedin.com\/in\/arundhati-parmar\/","https:\/\/x.com\/aparmarbb"],"url":"https:\/\/medcitynews.com\/author\/aparmar\/"}]}},"_links":{"self":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/users\/25944"}],"replies":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/comments?post=146464"}],"version-history":[{"count":10,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146464\/revisions"}],"predecessor-version":[{"id":146504,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146464\/revisions\/146504"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media\/15816"}],"wp:attachment":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media?parent=146464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/categories?post=146464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/tags?post=146464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}